Zacks Investment Research on MSN3h
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
TD Cowen Sticks to Their Buy Rating for Regeneron (REGN)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...
PMLive8h
Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma
Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...